Resources

Rinri Therapeutics is well-positioned to succeed in developing a therapy for hearing loss,  as they are now at the forefront of this rapidly evolving field and have established a strong  track record of innovation combined with preclinical and clinical progress.

In the HSC gene therapy approach pioneered by Orchard Therapeutics, working copies  of the faulty gene causing the disease is inserted and integrated into the genome of the  patients’ own HSCs.

It’s always positive to shine a spotlight on UK strengths, and it’s great that the UK is cementing its position as a global leader in cell and gene therapy. The UK's leadership in cell and gene therapy is a testament to our unwavering dedication to patient-centric advancements that rewrite the boundaries of healthcare, but others, like Wallonia,  are also keen to attract growth in this exciting area, so there is no room for complacency. 

Purespring’s platform has the potential for identifying and developing treatments for a large number of kidney diseases with unmet needs.

UK clinical trial growth has been encouraging. Cell and gene therapies represent a powerful and personalised treatment option and with the potential to become standard of care in many blood cancer and other indications. 

The UK is cementing its position as a global leader in cell and gene therapy, according to a new report released today by the UK BioIndustry Association (BIA), in collaboration with Citeline.  

In this blog, Professor James Fildes, CEO and Chief Scientist and Amy Stewart, Research Technician at Pebble Biotechnology Laboratories argue that the significant difference in human to mice gene expression in various tissues could explain why many drugs that are successful in rodents fail in humans.

Next-generation sequencing and many other tools provide tremendous new insights into human biology. Emerging techniques, such as CRISPR technology and cell and gene therapies are providing new opportunities to treat and possibly even cure some of the most intractable diseases.

The Genetic Technologies (Precision Breeding) Act was passed into law in England in March 2023 to enable the development and marketing of gene-edited crops and animals in England, allowing us to grow more resilient crops and breed animals that are more resistant to harmful diseases and put those to market.

Immunocore has been awarded the prestigious Prix Galien France 2022 award in the ‘Medicine in Innovative Therapeutics’ category, for KIMMTRAK® (tebentafusp), the world’s first T cell receptor therapy.